This federal Project Grant award of $275,737 from the National Institute on Deafness and Other Communication Disorders (NIDCD) under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) supports the development and in vivo validation of a machine learning platform to predict the ototoxic potential of pharmaceuticals. The grantee, Rewire Neuroscience LLC, aims to develop an innovative machine learning model that can rapidly and cost-effectively detect ototoxicity during preclinical drug development, before substantial time and capital are invested in lead compounds. The project will optimize the machine learning model, then experimentally validate its predictions using the zebrafish lateral line system as an in vivo ototoxicity testing platform. The ultimate goal is to create an online portal that allows customers to incorporate this ototoxicity prediction technology into their early-stage drug development pipelines.
Generated 3/25/25, 2:46 AM